# EDGAR Filing Document

**Accession Number:** 0001265521
**File Stem:** 0001641172-25-025989
**Filing Date:** 2025-8
**Character Count:** 34115
**Document Hash:** 3ca25a9eb694cb79603f132ae6caef66
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-025989.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0001641172-25-025989

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250829

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250829

**DATE AS OF CHANGE**: 20250829

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Polomar Health Services, Inc.
- **CENTRAL INDEX KEY:** 0001265521
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 861006313
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56555
- **FILM NUMBER:** 251281063

**BUSINESS ADDRESS:**
- **STREET 1:** 140 BROADWAY
- **STREET 2:** 46TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10005
- **BUSINESS PHONE:** 800-490-7454

**MAIL ADDRESS:**
- **STREET 1:** 140 BROADWAY
- **STREET 2:** 46TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Trustfeed Corp.
- **DATE OF NAME CHANGE:** 20230504

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HEALTHMED SERVICES LTD
- **DATE OF NAME CHANGE:** 20031001

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): August 29, 2025 (August 25, 2025)

**<u>Polomar Health Services, Inc.</u>**

(Exact name of registrant as specified in its charter)

<u>Nevada</u> <u>000-56555</u> <u>86-1006313</u> <br> (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

<u>32866 US Hwy. 19 N, Palm Harbor, FL</u> <u>34684</u> <br> (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: <u>727-425-7575</u>

<u>10940 Wilshire Blvd., Suite 1500, Los Angeles, CA, 90024</u> <br> (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: none

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**1.01 Entry into a Material Definitive Agreement.**

On August 25, 2025, Polomar Health Services, Inc., a Nevada corporation ("Company"), executed an Amended and Restated Product Fulfillment and Distribution Agreement, effective on August 19, 2025 (the "Amended Agreement") with ForHumanity, Inc., a Delaware corporation ("ForHumanity") and Island Group 40, LLC ("IG4").

The Amended Agreement allows ForHumanity to exclusively market (through March 31, 2026) the Company's previously licensed, patent pending, inhalable sildenafil and inhalable eletriptan. The Company shall be solely responsible for fulfilling valid prescriptions for these medications through our wholly owned subsidiary, Polomar Specialty Pharmacy, LLC ("Polomar"). IG4 provides account management services on behalf of the Company.

The Amended Agreement incorporates the following material terms:

The Amended Agreement is for an initial term of forty-two (42) months commencing on March 17, 2025, through September 16, 2028, and may be automatically renewed for additional terms pursuant to the terms of the Amended Agreement provided ForHumanity meets certain revenue commitments prior to the end of the initial term.

In exchange for guaranteed payments of $750,000 on or before October 31, 2025, $200,000 of which has been received by the Company, the Company has granted exclusivity to market the products to potential customers through March 31, 2026. Exclusivity may be extended through September 30, 2026, provided ForHumanity remits a minimum $1,500,000 in sales revenue to the Company prior to March 31, 2026. Exclusivity can be maintained by ForHumanity through December 31, 2026, provided the Company has received at least $3,000,000 in revenue prior to June 30, 2026. Should ForHumanity continue to meet certain minimum revenue goals as more fully described in the Amended Agreement then exclusivity can be maintained through the end of the initial term.

The foregoing summary of the Amended Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Amended Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated by reference herein. Exhibit A to the Amended Agreement is not included with this Current Report as Exhibit A contains confidential, proprietary and trade secret information that may violate the terms of the Amended Agreement.

**Cautionary Statement Regarding Forward-Looking Statements**

This report contains "forward-looking statements" within the meaning of the federal securities laws. All statements, other than statements of fact, that address activities, events or developments that we or our management intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe forward-looking statements are based upon reasonable assumptions, such statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results or performance of each company to be materially different from any future results or performance expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, (1) the risk that the previously licensed intellectual property may not be granted the pending patents, (2) the ability of ForHumanity to effectively market the licensed medications to increase customer value and financial returns, (3) the ability to integrate the ForHumanity telemedicine network into the existing Polomar business and realize the benefits of the Agreement, (4) the other risks described under the headings "Risk Factors" and "Cautionary Statement Concerning Forward-Looking Statements" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and such other periodic filings the Company makes from time to time with the Securities and Exchange Commission (SEC), including "Risk Factors" included in in our Current Report on Form 8-K dated October 4, 2024, as amended on October 25, 2024 and November 12, 2024.

You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are not guarantees of future performance, and actual results, developments, and business decisions may differ from those envisaged by our forward-looking statements. Except as required by law, we undertake no obligation to update such statements to reflect events or circumstances arising after the date of this press release, and we caution investors not to place undue reliance on any such forward-looking statements.

**Item 9.01 Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 10.1 | [Amended and Restated Product Fulfillment and Distribution Agreement between ForHumanity Health, Inc., Island 40 Group, LLC and Polomar Health Services, Inc., dated August 25, 2025.](ex10-1.htm) |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| |
|:---|
| **Trustfeed Corp.** |
| */s/ Terrence M. Tierney* |
| Terrence M. Tierney |
| President |
| Date: August 29, 2025 |

---

## Exhibit 10.1

**Exhibit 10.1**

**<u>Amended and Restated Polomar Health Services, Inc. Product Fulfillment</u>**

**<u>and Distribution Agreement</u>**

This Amended and Restated Fulfillment and Product Distribution Agreement (the "Restated Agreement") between Polomar Health Services, Inc. and Polomar Specialty Pharmacy, LLC ("Polomar"), a wholly owned subsidiary and (collectively, PMHS" or the "Company"), a publicly traded Nevada corporation, with a principal place of business located at 10940 Wilshire Blvd., Suite 1500, Los Angeles, CA 90024, Island 40 Group ("IG4"), a Tennessee limited liability company and FORHumanity Health, Inc. d/b/a ForHumanity ("FHH"), a Delaware Corporation, with a mailing address of 1041 Market Street #446, San Diego, CA 92101-7233. PMHS, IG4 and FHH are collectively referred to as Parties herein and each a Party.

**Whereas,** the Parties entered into that certain Fulfillment and Product Distribution Agreement (the "Agreement") effective March 12, 2025, and as amended on March 17, 2025 (the "First Amendment"; and

**Whereas,** the Parties desire to amend and restate the Agreement and First Amendment pursuant to the terms herein.

**Now Therefore**, the Parties hereto agree as follows:

1. **<u>Territory.</u>** The Territory shall include all U.S. states and U.S. Territories in which Polomar Specialty Pharmacy, LLC ("Polomar") is presently licensed or may become licensed during the term of this agreement.

2. **<u>Term/Termination.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The term of this Agreement shall be for a term of forty-two months (42) commencing on March 17, 2025, and terminating on September 16, 2028 ("Initial Term"), unless otherwise renewed pursuant to the terms herein below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) This Agreement shall automatically renew for an additional thirty-six (36) month term provided minimum average annual gross revenues received by PMHS from FHH during the Initial Term are not less than $3,000,000 ("1<sup>st</sup> Renewal Term").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) This Agreement shall automatically renew for an additional sixty (60) month term provided minimum average annual gross revenues received by PMHS from FHH during the 1<sup>st</sup> Renewal Term are not less than $6,000,000 ("2<sup>nd</sup> Renewal Term")

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) If FHH meets or exceeds its Exclusivity Goal (as defined in Section 7(g) hereinbelow), then this Agreement shall continue to renew for additional five (5) year terms unless otherwise terminated pursuant to the terms hereof.

This Agreement may be terminated upon ninety (90) days written notice of either Party to the other Party, if monthly average gross revenues ("Average Revenues") payable by FHH to PMHS are less than $100,000 per month commencing on October 1, 2025 through July 30, 2026 or for gross negligence or gross misconduct by either Party, if the negligence or misconduct is not cured within 30 days after receipt of notice from the non-breaching Party.

3. **<u>Account Management.</u>**

Island 40 Group, LLC ("IG4") is PMHS's exclusive commercial account management partner. FHH shall communicate directly with IG4 on all matters relating to sales hereunder.

FHH may contact PMHS directly if IG4 fails to respond within 48 hours or in cases of urgent supply or quality issues, with notice to IG4.

5. **<u>Pricing</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Parties hereto shall agree to initial product pricing as disclosed on Exhibit A, attached hereto and made a part hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) product price increase due to market conditions (i.e. tariffs, raw material price increases of more than 3%, etc.) shall be allowed with documented proof provided to FHH of the market condition and communicated to FHH on at least ninety (90) days written notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) PMHS may not raise product prices more than three percent (3%) per year during the Initial Term of this agreement or any Renewal Term.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) PMHS/IG4 shall not charge FHH more for products delivered to FHH pursuant to this Agreement than PMHS/IG4 charges any other customer of PMHS/IG4.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) FHH, upon forty-five (45) days notice, may audit PMHS/IG4's pricing records annually. If discrepancies exceeding 2% are found, audit costs shall be borne by PMHS/IG4.

6. **<u>Sales Forecast</u>**. Within ninety (90) days of commencement of sales of Polomar products to customers of FHH, FFH must provide a twelve (12) month forecast of sales, by product to IG4, and every quarter subsequently so that IG4 can ensure sufficient product availability and supply. Should FFH become aware of a material deviation (+/- 10%) from any Sales Forecast provided to IG4 hereunder, then FHH must notify IG4 within five (5) business days with an updated Sales Forecast.

7. **<u>Product Availability/ Exclusivity Terms</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;(a) FHH
 will be the exclusive partner for inhalable sildenafil, inhaled eletriptan (or such other
 inhalable triptan medication(s) as the Parties may agree upon), and, pursuant to a first
 refusal right, any other new dry inhalable products (collectively, "Dry Inhalables")
 offered for sale by PMHS through March 31, 2026, in exchange for a product purchase guarantee
 of not less than $750,000.

(b) It
 is further agreed that should PMHS receive total Revenues from FHH of $1,500,000 on or before
 March 31, 2026, then exclusivity for all Dry Inhalables shall be extended through September
 30, 2026.

(c) It
 is further agreed that should PMHS receive total Revenues from FHH of $3,000,000 between
 January 1, 2026, and June 30, 2026, then exclusivity for all Dry Inhalables shall be extended
 through December 31, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;(d) It
 is further agreed that should PMHS receive total Revenues from FHH of $8,000,000 for the
 fiscal year ending on December 31, 2026, then exclusivity for all Dry Inhalables shall be
 extended through June 30, 2027.

(e) It
 is further agreed that should PMHS receive total Revenues from FHH of $8,000,000 for the
 calendar period January 1, 2027, through June 30, 2027 then exclusivity for all Dry Inhalables
 shall be extended until December 31, 2027.

(f) It
 is further agreed that should PMHS receive total Revenues from FHH of $20,000,000 for the
 fiscal year ending on December 31, 2027, then exclusivity for all Dry Inhalables shall be
 extended until December 31, 2028.

(g) In
 all subsequent calendar years after the fiscal year ending on December 31, 2027, FHH hereby
 agrees to an annual thirty percent (30%) increase over the prior year's Exclusivity
 Goal to maintain exclusivity hereunder ("Exclusivity Goal"). If the Exclusivity
 Goal is achieved, exclusivity for all Dry Inhalables shall be extended for the following
 calendar year; therefore, Ex., the Exclusivity Goal for 2028 Revenues from FHH to PMHS will
 be $26,000,000 and shall confer exclusivity through 2029. This paragraph 7(g) shall apply
 to all renewal terms of this Agreement.

(h) PMHS
 shall immediately reserve, 8,000 kits of inhalable sildenafil, each kit consisting of two
 (2) inhalers and ten (10) capsules of 25 mg inhalable sildenafil, for the exclusive use of
 FHH pursuant to the terms herein.

(i) PMHS
 shall manufacture and reserve, upon completion of appropriate PK clinical studies, 8,000inhalable
 eletriptan kits, each kit consisting of two (2) inhalers and ten (10) capsules of inhalable
 eletripta , for the exclusive use of FHH pursuant to the terms herein.

(j) PMHS
 shall utilize reasonable commercial efforts to have clinical PK data on inhalable eletriptan
 within ninety (90) days of the date of this Restated Agreement.

(k) PMHS
 acknowledges receipt of advance payments totaling $200,000 to secure the exclusivity granted
 herein above.

(l) FHH
 and PMHS shall utilize their best efforts to enter into a joint venture to co-develop a kiosk
 vending POS solution for the delivery of the products contemplated herein as well as any
 other prescription and non-prescription (over-the-counter) medications that PMHS deems in
 its sole discretion are commercially viable.

(m) The
 following sales of any Dry Inhalables shall not be subject to the Product Exclusivity provisions
 herein above:

i) sales to clinics, hospitals or physician practices; and <br>ii) sales to governmental agencies.

&nbsp;&nbsp;&nbsp;&nbsp;(n) IG4
 and PMHS shall also utilize their best efforts to prioritize FHH product availability for
 products being supplied to FHH and shall notify FHH within five (5) business days if they
 believe they may not be able to meet the product requirements as disclosed in the Sales Forecast.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i) If PMHS does not ship product to FHH or their customers, ordered in a given month, then that month or year's Exclusivity Goal will be calculated as if that product had shipped as long as those orders were made in good faith and consistent with the FHH sales forecast.

8. **<u>New Product Availability</u>**. Any new Polomar or IG4 pharmaceutical, nutraceutical, or peptide products or any new proprietary systems and technology for the ingestion and/or consumption of our products to patients shall be made available for sale to FFH at the same time or prior to any other sales or distribution clients. Exclusivity for new products shall be subject to a separate agreement.

9. Intentionally Left Blank

10. **<u>Payment Terms</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) FHH payment terms on product shipping provided by PMHS/IG4 shall be within seven (7) business days of receipt of the invoice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) FHH shall be solely responsible for the purchase price for any custom designed product packaging, including, but not limited to branded capsules, containers, inhalers or other collateral materials.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) FHH shall pay all shipping on any custom designed products or packaging.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) FHH shall make an additional advance payment hereunder in the amount of $50,000 on or before September 15, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Payment Terms for the remaining $500,000 of the opening exclusivity order shall be due on or before October 31, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) PMHS shall invoice FHH for product monthly subsequent to the opening exclusivity order with fifteen (15) day payment terms from the date of invoice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) If FHH makes future reserve orders, those invoices shall be paid one-third upon submission of order and the remaining balance within sixty (60) days after the date of the order.

11. **<u>Product Quality</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;(a) PMHS
 guarantees that all products provided to FHH shall be manufactured in FDA cGMP licensed outsourcing
 or contract manufacturing facilities; and

&nbsp;&nbsp;&nbsp;&nbsp;(b) PMHS
 strictly adheres to USP guidelines in the sourcing of API's and related ingredients;
 and

&nbsp;&nbsp;&nbsp;&nbsp;(c) Upon
 request, PMHS shall provide to FHH product test results and certificates of authentication.

&nbsp;&nbsp;&nbsp;&nbsp;(d) If
 n the event of any product recall, PMHS shall, within twenty-four (24) hours, notify FHH
 of the recall, the nature of the recall and PMHS's remediation plan, with all costs
 associated with any recall to be borne by PMHS.

12. **<u>Wholesale Customer Opportunities</u>**.

FHH may from time to time come across additional wholesale customer sales opportunities. FHH, upon notifying I4G in writing of this opportunity, shall have a six (6) month exclusivity period to negotiate a sales and distribution agreement with the identified potential wholesale customers. If FHH completes a sale with a wholesale customer during the exclusivity period, then that customer shall be FHH's exclusive customer during the term hereof any renewal hereof and for a period of three (3) years after the termination of this agreement or the final shipment of any product(s) to the customer.

13. **<u>Confidentiality.</u>**

The Parties hereto shall during the term of this Agreement and for a period of two (2) years following the termination of this Agreement keep confidential the terms of this Agreement, except as disclosure may be required by the U.S. Securities and Exchange Commission.

The Parties agree to mutually keep confidential the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) business
 records and plans, trade secrets, technical information, products, pricing structure, discounts,
 costs, licenses, customer lists, copyrights and other intellectual property and any other
 proprietary information.

The Parties agree the following is not considered "confidential information":

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) matters
 of public knowledge that result from previous disclosures made by either Party, information
 rightfully received by either Party from a third Party without a duty of confidentiality,
 information independently developed by either Party, information disclosed by operation of
 law, information disclosed by FHH with the prior written consent of PMHS, and any other information
 that the Parties agree in writing is not confidential.

14. **<u>Non-solicitation</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Parties hereto agree that for a period of two (2) years from any termination of this agreement that no Party shall solicit customers from any Party hereto; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Parties hereto agree that for a period of one (2) year from any termination of this agreement that no Party shall solicit employees from any Party hereto

15. **<u>Indemnification</u>.** PMHS/I4G agrees to indemnify and hold harmless FHH and its directors, officers and affiliates against any and all losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses and disbursements (and all actions, suits, proceedings and investigations in respect thereof and any and all legal or other costs, expenses and disbursements in giving testimony or furnishing documents in response to a subpoena or otherwise), including, without limitation, the costs, expenses, and disbursements, as and when incurred, of investigating, preparing or defending any such action, proceeding or investigation (whether or not in connection with litigation to which FHH is a Party), directly or indirectly, caused by, relating to, based upon, arising out of or in connection with information provided by the Company which contains a material misrepresentation or material omission in connection with the provision of services by FHH under this Agreement; provided however, such indemnity agreement shall not apply to any portion of any such loss, claim, damage, obligation, penalty, judgment, award, liability, cost, expense or disbursement to the extent it is found by a court of competent jurisdiction to have resulted from negligence or willful misconduct of FHH. For example, FHH's indemnification shall not extend to claims arising from PMHS/IG4's manufacturing defects, quality issues, or failure to meet FDA or other regulatory standards.

Each Party entitled to indemnification under this agreement (the "Indemnified Party"), shall give notice to the Party required to provide indemnification (the "Indemnifying Party") promptly, within thirty (30) days, after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting there from, provided that counsel for the Indemnifying Party, who shall conduct the defense at such claim or any litigation resulting there from, shall be approved by the Indemnified Party (whose approval shall not be unreasonably withheld), and the Indemnified Party may participate in such defense at such Party's expense, and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section 7. Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and as shall be reasonably required in connection with defense of such claim and any litigation resulting therefrom.

Notwithstanding the foregoing, FHH shall indemnify and hold harmless PMHS/I4G, its directors, officers, subsidiaries and affiliates against any and all losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses and disbursements resulting from any actions taken, claims made, or misrepresentations by FHH regarding the products and services provided by PMHS its subsidiaries and affiliates pursuant to this Agreement.

16. **<u>Insurance</u>.** Each Party hereto shall maintain minimum general liability insurance of not less than $2,000,000 in the aggregate, $1,000,000 per occurrence. Additionally, Polomar Specialty Pharmacy, LLC shall maintain product liability insurance in an amount not less than $3,000,000 aggregate.

17. **<u>Arbitration</u>**. If a dispute arises from or relates to this contract or the breach thereof, and if the dispute cannot be settled through direct discussions, the parties agree to endeavor first to settle the dispute by mediation administered by the American Arbitration Association under its Commercial Mediation Procedures before resorting to arbitration. The parties further agree that any unresolved controversy or claim arising out of or relating to this contract, or breach thereof, shall be settled by arbitration administered by the American Arbitration Association in accordance with its Commercial Arbitration Rules and judgment on the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof. Claims shall be heard by a single arbitrator, unless the claim amount exceeds $2,000,000.00, in which case the dispute shall be heard by a panel of three arbitrators.

Any arbitration hearing shall be held in a mutually agreed upon location or via virtual proceedings. Notwithstanding the foregoing, the parties shall utilize their best efforts to hold all settlement conferences, mediation or arbitration proceedings remotely. Each Party hereto shall bear its own costs unless the arbitrator renders a finding of bad faith, in which case fees may shift. The arbitration shall be governed by the laws of the State of Delaware Depositions shall be limited to a maximum of two (2) per Party and shall be held within 21 days of the making of a request. Additional depositions may be scheduled only with the permission of the arbitrators, and for good cause shown. Each deposition shall be limited to a maximum of three (3) hours. In making determinations regarding the scope of exchange of electronic information, the arbitrator(s) and the parties agree to be guided by The Sedona Principles, Third Edition: Best Practices, Recommendations & Principles for Addressing Electronic Document Production.

The award shall be made within 9 months of the filing of the notice of intention to arbitrate (demand), and the arbitrator(s) shall agree to comply with this schedule before accepting appointment. However, this time limit may be extended by the arbitrator for good cause shown, or by mutual agreement of the parties.

The arbitrator(s) shall not award consequential damages in any arbitration initiated under this section. The arbitrator(s) shall award to the prevailing Party, if any, as determined by the arbitrators, all of their costs and fees. 'Costs and fees' mean all reasonable pre-award expenses of the arbitration, including the arbitrators' fees, administrative fees, travel expenses, out-of-pocket expenses such as copying and telephone, court costs, witness fees, and attorneys' fees. The award of the arbitrators shall be accompanied by a reasoned opinion. Except as may be required by law, neither a Party nor an arbitrator may disclose the existence, content, or results of any arbitration hereunder without the prior written consent of both parties. The parties agree that failure or refusal of a Party to pay its required share of the deposits for arbitrator compensation or administrative charges shall constitute a waiver by that Party to present evidence or cross-examine witness. In such event, the other Party shall be required to present evidence and legal argument as the arbitrator(s) may require for the making of an award. Such waiver shall not allow for a default judgment against the non-paying Party in the absence of evidence presented as provided for above. Notwithstanding any language to the contrary in the contract documents, the parties hereby agree: that the Underlying Award may be appealed pursuant to the AAA's Optional Appellate Arbitration Rules ("Appellate Rules"); that the Underlying Award rendered by the arbitrator(s) shall, at a minimum, be a reasoned award; and that the Underlying Award shall not be considered final until after the time for filing the notice of appeal pursuant to the Appellate Rules has expired. Appeals must be initiated within thirty (30) days of receipt of an Underlying Award, as defined by Rule A-3 of the Appellate Rules, by filing a Notice of Appeal with any AAA office. Following the appeal process the decision rendered by the appeal tribunal may be entered in any court having jurisdiction thereof.

18. **<u>Governing Law.</u>** This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware

19. **<u>Notices.</u>** All written notices required herein shall be sent electronically as follows:

As to PMHS: Terrence M. Tierney

President

<u>Terrence.Tierney@PolomarHS.com</u>

As to I4G: Casey Barksdale

<u>casey@island40group.com</u>

As to FHH: Douglas G. Paulin CPA

Chief Financial Officer

<u>douglas@forhumanity.co</u>

20. **<u>Force Majeure</u>.** The obligation of Polomar/IG4to provide prescription fulfillment services here under shall be suspended during the period and to the extent that Polomar/IG4 is prevented or hindered from complying therewith by any law or governmental order, rule, regulation or direction, whether domestic or foreign, or by any cause beyond the reasonable control of Polomar/IG4, including but not limited to acts of nature, strikes, lock outs and other labor and industrial disputes and disturbances, civil disturbances, accidents, acts of terrorism, acts of war or conditions arising out of or attributable to war (whether declared or undeclared), disease, epidemic, shortage of necessary equipment, materials or labor, or restrictions thereon or limitations upon the use thereof, and delays in transportation. In such event, Polomar/IG4 shall give notice of suspension as soon as reasonably practicable stating the date and extent of such suspension and the cause thereof and Polomar/IG4 best estimate of the date on which it will be able to resume the performance of its obligations herein. In addition, Polomar/IG4 will use commercially reasonable efforts during any such suspension to keep IG4 informed as to the progress of removal of the cause of such suspension. Polomar/IG4 shall resume the performance of such obligations as soon as reasonably practicable after the removal of the cause and Polomar/IG4 shall timely notify FHH, and Polomar/IG4 shall not be liable for failure to provide prescription fulfillment services for the period in which such Service could not be provided or granted pursuant to this paragraph. Notwithstanding the foregoing, Polomar/IG4 will utilize its commercially best efforts to provide prescription fulfillment services to FHH during any suspension of obligations provided for in this paragraph through other duly licensed vendors.

The Parties hereto agree to the terms of this Restated Agreement effective August 19, 2025.

**FOR HUMANITY HEALTH, INC.**

---

| | |
|:---|:---|
| */s/ Yoshua Davis* | */s/ Yoshua Davis* |
| Signature | Signature |
| By: | Yoshua Davis |
| Title: | Founder/President |

---

**ISLAND 40 GROUP, LLC**

---

| | |
|:---|:---|
| */s/ Casey Barksdale* | */s/ Casey Barksdale* |
| Signature |  |
| By: | Casey Barksdale |
| Title: | President |

---

**POLOMAR HEALTH SERVICES, INC.** 

---

| | |
|:---|:---|
| */s/ Terrence M. Tierney* | */s/ Terrence M. Tierney* |
| Signature |  |
| By: | Terrence M. Tierney |
| Title: | President |

---